Increased expression of galectin-1 during the progression of cervical neoplasia

International Journal of Gynecological Cancer

Volumn 16, Issue 6, 2006, Pages 2018-2022

  Kohrenhagen, N ^a   Volker, H U ^a   Kapp, M ^a   Dietl, J ^a   Kammerer, U ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cervical intraepithelial neoplasia; Cervix neoplasm; Galectin 1; Immunohistochemistry; Squamous cell

Indexed keywords

GALAPTIN; GALECTIN 1;

ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; METASTASIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TISSUE SECTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

DISEASE PROGRESSION; FEMALE; GALECTIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 33845515873     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00741.x     Document Type: Article

References (45)

1. Becker N, Wahrendorf J. Atlas of cancer mortality in the Federal Republic of Germany, 3rd edn. Heidelberg, Germany: Springer-Verlag, 2002. Available at http://www.dkfz.de.
2. Ackermann S, Beckmann MW, Altgassen C. Therapie des Zervixkarzinoms. Moderne operative Ansätze. Der Gynäkologe 2004;37:674-80.
3. DiSaia PJ, Creasman WJ, editors. Preinvasive disease of the cervix. In: Clinical gynaecologic oncology, 6th edn. St. Louis, MO: Mosby, 2002:1-34.
4. Richart RM. A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol 1990;75:131-3.
5. Liotta LA. Tumour invasion and metastases-role of extracellular matrix. Rhoads Memorial Award lecture. Cancer Res 1986;46:1-7.
6. Barondes SH, Castronovo V, Cooper DNW. Galectins: a family of animal β-galactosids binding lectins. Cell 1994;76:597-8.
7. Barondes SH, Cooper DNW, Gitt MA, Leffler H. Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-10.
8. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002;1572:263-73.
9. Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y, Kirino T. Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 2000;59:722-30.
10. Honjo Y, Nangia-Makker P, Inohara H, Raz A. Downregulation of galectin-3 suppresses tumourigenicity of human breast carcinoma cells. Clin Cancer Res 2001;7:661-8.
11. Yoshii T. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001;18:787-92.
12. Hughes RC. Galectins as modulators of cell adhesion. Biochimie 2001;83:667-76.
13. Ochieng J, Furtac V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004;19:527-35.
14. Kuwabara I, Sano H, Liu FT. Functions of galectins in cell adhesion and chemotaxis. Meth Enzymol 2003;363:532-52.
15. Gabius HJ, Brehler R, Schauer A, Cramer F. Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas. Virchows Arch (Cell Pathol) 1996;52:107-115.
16. Irimura T, Matsushita Y, Sutton RC et al. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991;51:387-93.
17. Lotan R, Matsushita Y, Ohannesian D et al. Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumour progression. Carbohydr Res 1991;213:47-57.
18. Gillenwater A, Xu XC, el-Naggar AK, Clayman GL, Lotan R. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996;18:422-32.
19. Cindolo L, Benvenuto G, Salvatore P et al. Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 1999;84:39-43.
20. Chiariotta L, Berlingieri MT, Battaglia C, Berger N, Bruni CB, Fusco A. Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 1992;7:2507-11.
21. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumours. Potential diagnostic implications. Am J Pathol 1995;147:815-22.
22. Van den Brule FA, Buicu C, Berchuck A et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 1996;27:1185-91.
23. Rorive S, Belot N, Decaestecker C et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumour astrocytes into the brain parenchyma. Glia 2001;33:241-55.
24. Van den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001;193:80-7.
25. Kopitz J, von Reitzenstein C, Andre S et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 2001;276:35917-23.
26. Wells V, Davies D, Mallucci L. Cell cycle arrest and induction of apoptosis by beta galactoside binding protein (beta GBP) in human mammary cancer cells. A potential new approach to cancer control. Eur J Cancer 1999;35:978-83.
27. Cooper DN, Massa SM, Barondes SH. Endogenous muscle lectin inhibits myoblast adhesion to laminin. J Cell Biol 1991;115:1437-48.
28. Castronovo V, Luyten F, van den Brule F, Sobel ME. Identification of a 14-kDa laminin binding protein (HLBP14) in human melanoma cells that is identical to the 14-kDa galactoside binding lectin. Arch Biochem Biophys 1991;297:132-8.
29. Ohannesian DW, Lotan D, Lotan R. Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1 and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 1991;54:5992-6000.
30. Ozeki Y, Matsui T, Yamamoto Y, Funahashi M, Hamako J, Titani K. Tissue fibronectin is an endogenous ligand for galectin-1. Glycobiology 1995;5:255-61.
31. Wasano K, Hirakawa Y. Recombinant galectin-1 recognizes mucin and epithelial cell surface glycocalyces of gastrointestinal tract. J Histochem Cytochem 1997;45:275-83.
32. Ellerhorst J, Nguyen T, Cooper DN, Lotan D, Lotan R. Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol 1999;14:217-24.
33. Van den Brule F, Califice S, Garnier F, Fernandez PL, Berchuck A, Castronovo V. Galectin-1 accumulation in the ovary carcinoma peritumoural stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest 2003;83:377-86.
34. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T-cells mediated by galectin-1. Nature 1995;378:736-9.
35. Blaser C, Kaufmann M, Muller C et al. Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 1998;28:2311-9.
36. Rabinovich GA, Iglesias MM, Modesti NM et al. Activated rat macrophages produce a galectin-1 protein that induces apoptosis of T-cells: biochemical and functional characterization. J Immunol 1998;160:4831-40.
37. Chung CD, Patel VP, Moran M, Lewis LA, Miceli MC. Galectin-1 induces partial TCR beta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 2000;165:3722-9.
38. Matarrese P, Tinari A, Mormone E et al. Galectin-1 sensitizes resting human T-lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding and fission. J Biol Chem 2005;280:3801-11.
39. Rubinstein N, Alvarez M, Zwirner NW et al. Targeted inhibition of galectin-1 gene expression in tumour cells results in heightened T-cell-mediated rejection; a potential mechanism of tumour-immune privilege. Cancer Cell 2004;5:241-51.
40. Lee JW, Song SY, Choi JJ et al. Decreased galectin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol 2005;132:241-74.
41. Rabinovich GA, Gruppi A. Gelatins as immunoregulators during infectious processes: from microbial invasion to the resolution of the disease. Parasite Immunol 2005;27:103-14.
42. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002;1572:285-93.
43. Noel A, Foidart JM. The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998;3:215-25.
44. Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667-71.
45. Van den Brule FA, Waltregny D, Liu FT, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-7.